Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)

Phase 3

BAYER (BAYRY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Pain

LTGOJournavx

VRTXSuzetrigine

Phase 3

JNJAcetaminophen/Naproxen Sodium Fixed Combination

Drug Information

Target Indication

Pain

Clinical Trial

NCT01365052

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts